Edwards Lifesciences (EW) Non-Current Debt (2009 - 2026)

Edwards Lifesciences' Non-Current Debt history runs 18 years deep, the most recent figure standing at $598.5 million for Q1 2026.

• In Q1 2026, Non-Current Debt changed 0.12% year-over-year to $598.5 million; the TTM figure through Mar 2026 stood at $598.5 million (changed 0.12% YoY), while the FY2025 annual figure was $598.3 million, changed 0.1% from the prior year.
• Non-Current Debt was $598.5 million for Q1 2026 at Edwards Lifesciences, roughly flat from $598.3 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $598.5 million in Q1 2026 to a low of $595.9 million in Q1 2022.
• Historically, Non-Current Debt has averaged $597.2 million across 5 years, with a median of $597.2 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Non-Current Debt rose 0.12% in 2022, then rose 0.1% in 2025.
• A 5-year view of Non-Current Debt shows it stood at $596.3 million in 2022, then increased by 0.12% to $597.0 million in 2023, then grew by 0.12% to $597.7 million in 2024, then increased by 0.1% to $598.3 million in 2025, then gained by 0.03% to $598.5 million in 2026.
• The last three Non-Current Debt figures came in at $598.5 million (Q1 2026), $598.3 million (Q4 2025), and $598.2 million (Q3 2025), per Business Quant data.